ROIV gets FDA approval for targeted oral dermatomyositis therapy
ROIV says the FDA approved LISRAYA as the first targeted oral therapy for adult dermatomyositis.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.